论文部分内容阅读
目的 :研究肝癌患者血清GLS含量及其临床意义。方法 :测定肝癌、非癌肝病患者和健康人GLS ,然后分组统计。结果 :肝癌组GLS(799± 2 2 6mg/L)显著高于健康组 (4 6 6± 6 5mg/L)和各良性肝病组 ;各良性肝病组与健康组无明显差异。测定GLS对肝癌诊断敏感度、特异度、准确度和诊断效率分别为 82 4 %、94 7%、89 7%和 78 0 % ,具有显著临床应用价值 ,并且高于血清AFP测定。测定GLS与AFP联合应用诊断价值更为显著。结论 :肝癌患者血清GLS显著增加 ;其测定对肝癌诊断、病情及疗效监测、预后分析具有显著临床价值 ;与AFP联合检测临床价值更显著
Objective: To study the serum GLS level in patients with liver cancer and its clinical significance. Methods: GLS was determined in patients with hepatocellular carcinoma, non-cancerous liver disease and healthy individuals, and then grouped by statistics. Results: GLS (799 ± 226 mg / L) in liver cancer group was significantly higher than that in healthy group (466 ± 65 mg / L) and benign liver disease group. There was no significant difference between benign liver disease group and healthy group. The sensitivity, specificity, accuracy and diagnostic efficiency of GLS for the diagnosis of liver cancer were 82 4%, 94 7%, 89 7% and 78 0%, respectively, which had significant clinical value and were higher than serum AFP. Determination of GLS and AFP combined application of diagnostic value even more significant. Conclusion: The serum GLS of patients with hepatocellular carcinoma was significantly increased. The determination of serum GLS in patients with hepatocellular carcinoma has significant clinical value in the diagnosis, prognosis and prognosis of hepatocellular carcinoma. The clinical value of combined detection with AFP is more significant